Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is trending lower in pre-market trading as markets react to Adaptive plans business separation.
The company announced yesterday about its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Adaptive Biotechnologies is evaluating strategic and structural alternatives for Immune Medicine to support its growth strategy, capital needs, and value creation opportunities outside of the company, and expects to identify its preferred path to separation by year-end 2026.
The MRD has evolved into a profitable, leading business in MRD diagnostics, whereas Immune Medicine has developed a unique discovery platform that leverages proprietary immune data and artificial intelligence.
The stock hovered near $16.11 in pre-market trading following a previous close of $17.46.
 is trending lower in pre-market trading as markets react to Adaptive plans business separation.~br~Adaptive Biotechnologies Corporation announced its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses.){kind=link}